NuVasive PT Raised to $35.00 at Needham & Company (NUVA)
Research analysts at Needham & Company lifted their target price on shares of NuVasive (NASDAQ:NUVA) from $28.00 to $35.00 in a report released on Wednesday, American Banking News reports. The firm currently has a “buy” rating on the stock. Needham & Company’s target price would suggest a potential upside of 12.11% from the company’s current price.
In other NuVasive news, EVP Jason Hannon sold 2,334 shares of the company’s stock on the open market in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $28.90, for a total value of $67,452.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of NuVasive (NASDAQ:NUVA) opened at 31.22 on Wednesday. NuVasive has a one year low of $13.05 and a one year high of $32.33. The stock has a 50-day moving average of $25.43 and a 200-day moving average of $23.88. The company’s market cap is $1.391 billion.
NuVasive (NASDAQ:NUVA) last released its earnings data on Tuesday, October 29th. The company reported $0.39 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.24 by $0.15. The company had revenue of $169.20 million for the quarter, compared to the consensus estimate of $158.30 million. During the same quarter in the prior year, the company posted $0.23 earnings per share. The company’s quarterly revenue was up 14.0% on a year-over-year basis. Analysts expect that NuVasive will post $1.12 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Goldman Sachs Group Inc. downgraded shares of NuVasive from a “neutral” rating to a “sell” rating in a research note to investors on Monday, October 14th. They now have a $22.00 price target on the stock, down previously from $25.00. Analysts at BMO Capital Markets upgraded shares of NuVasive from an “underperform” rating to a “market perform” rating in a research note to investors on Monday, October 14th. They now have a $25.00 price target on the stock, up previously from $22.00. One analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $28.24.
NuVasive, Inc (NASDAQ:NUVA) is a medical device company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.